Holen Sie sich die Stockscreener-App
5.02
1.47%
-0.08
Schlusskurs vom Vortag:
$5.10
Offen:
$5.13
24-Stunden-Volumen:
365.46K
Relative Volume:
0.59
Marktkapitalisierung:
$253.11M
Einnahmen:
$230.47M
Nettoeinkommen (Verlust:
$30.28M
KGV:
8.2295
EPS:
0.61
Netto-Cashflow:
$38.86M
1W Leistung:
-4.65%
1M Leistung:
-2.05%
6M Leistung:
+56.54%
1J Leistung:
+70.34%
1-Tages-Spanne:
$5.00
$5.22
1-Wochen-Bereich:
$5.00
$5.515
52-Wochen-Spanne:
$2.32
$6.07
Puma Biotechnology Inc Stock (PBYI) Company Profile
Firmenname
Puma Biotechnology Inc
Sektor
Branche
Telefon
(424) 248-6500
Adresse
10880 WILSHIRE BLVD., LOS ANGELES, CA
Vergleichen Sie PBYI mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
PBYI
Puma Biotechnology Inc
|
5.025 | 256.89M | 230.47M | 30.28M | 38.86M | 0.61 |
|
VRTX
Vertex Pharmaceuticals Inc
|
425.27 | 109.11B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
642.15 | 68.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
431.02 | 60.25B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
825.35 | 50.39B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
186.61 | 40.44B | 447.02M | -1.18B | -868.57M | -6.1812 |
Puma Biotechnology Inc Stock (PBYI) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2021-09-28 | Hochstufung | Citigroup | Neutral → Buy |
| 2020-06-25 | Fortgesetzt | BofA/Merrill | Underperform |
| 2019-10-08 | Herabstufung | Goldman | Neutral → Sell |
| 2019-05-10 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2019-05-10 | Herabstufung | Citigroup | Buy → Neutral |
| 2019-01-17 | Eingeleitet | Leerink Partners | Mkt Perform |
| 2019-01-03 | Herabstufung | Guggenheim | Buy → Neutral |
| 2018-11-19 | Hochstufung | Goldman | Sell → Neutral |
| 2018-11-02 | Herabstufung | BofA/Merrill | Buy → Underperform |
| 2018-11-02 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2018-10-01 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2018-09-17 | Eingeleitet | Goldman | Sell |
| 2018-05-11 | Bestätigt | Stifel | Buy |
| 2017-11-10 | Bestätigt | Citigroup | Buy |
| 2017-11-10 | Bestätigt | RBC Capital Mkts | Sector Perform |
| 2017-10-02 | Bestätigt | Stifel | Buy |
| 2017-09-11 | Bestätigt | Credit Suisse | Outperform |
| 2017-07-10 | Fortgesetzt | Leerink Partners | Outperform |
| 2017-06-06 | Bestätigt | RBC Capital Mkts | Sector Perform |
| 2017-05-25 | Bestätigt | RBC Capital Mkts | Sector Perform |
| 2017-03-02 | Bestätigt | RBC Capital Mkts | Sector Perform |
Alle ansehen
Puma Biotechnology Inc Aktie (PBYI) Neueste Nachrichten
Using R and stats models for Puma Biotechnology Inc. forecasting2025 Institutional Moves & Weekly High Potential Alerts - newser.com
How strong is Puma Biotechnology Inc. stock revenue growthPortfolio Performance Report & Fast Entry High Yield Tips - newser.com
Using Ichimoku Cloud for Puma Biotechnology Inc. technicalsMarket Risk Analysis & Stock Portfolio Risk Management - newser.com
How institutional buying supports Puma Biotechnology Inc. stockMarket Activity Report & Daily Oversold Bounce Ideas - newser.com
Is Puma Biotechnology Inc. reversing from oversold territoryJuly 2025 Levels & Verified Chart Pattern Trade Signals - newser.com
Can Puma Biotechnology Inc. stock withstand economic slowdown2025 Historical Comparison & AI Enhanced Trading Signals - newser.com
Global Desmoid Tumors Market Report 2025: Regional and Country-Level Analysis & Forecast to 2035 Featuring SpringWorks Therapeutics, Ayala Pharma, Puma Biotechnology, BMS, Eli Lilly, Ipsen, Deciphera Pharma - Yahoo Finance
Puma Biotechnology (PBYI) Projected to Post Quarterly Earnings on Thursday - MarketBeat
Will Puma Biotechnology Inc. stock remain a Wall Street favorite - fcp.pa.gov.br
Puma Biotechnology (NASDAQ:PBYI) Downgraded to Hold (C+) Rating by Weiss Ratings - MarketBeat
Puma Biotechnology to Host Conference Call to Discuss Third Quarter 2025 Financial Results - BioSpace
Puma Biotechnology to Host Conference Call to Discuss Third Quarter Financial Results - The AI Journal
Puma Biotechnology targets $192M-$198M NERLYNX revenue for 2025 amid strategic efforts - MSN
Why Puma Biotechnology Inc. is moving todayJuly 2025 Earnings & AI Enhanced Market Trend Forecasts - newser.com
Is Puma Biotechnology Inc. stock a safe investment in uncertain marketsProduct Launch & Short-Term Trading Opportunity Alerts - newser.com
Chart overlay techniques for tracking Puma Biotechnology Inc.Fed Meeting & Smart Money Movement Alerts - newser.com
Exit strategy if you’re trapped in Puma Biotechnology Inc.Bear Alert & Low Drawdown Momentum Trade Ideas - newser.com
Relative strength of Puma Biotechnology Inc. in sector analysisQuarterly Portfolio Report & Safe Capital Growth Tips - newser.com
Is now a turning point for Puma Biotechnology Inc.July 2025 Technicals & Verified Entry Point Signals - newser.com
Finanzdaten der Puma Biotechnology Inc-Aktie (PBYI)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.15%
1.65%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):